FDA ON-LABEL PROMOTION REGULATION WOULD HINGE ON SHOWING OF LIKELY HARM
Executive Summary
FDA's authority to take action against promotions for approved uses of drugs would be limited to cases where the agency determined that the promotional information "is likely to cause misuse of the drug in a way that is unsafe or ineffective," Pharmaceutical Research & Manufacturers of America FDA reform language proposes.